Operating Income (Loss) in USD of UNITED THERAPEUTICS Corp from Q1 2010 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
UNITED THERAPEUTICS Corp quarterly/annual Operating Income (Loss) history and change rate from Q1 2010 to Q3 2025.
  • UNITED THERAPEUTICS Corp Operating Income (Loss) for the quarter ending 30 Sep 2025 was $389M, a 13.2% increase year-over-year.
  • UNITED THERAPEUTICS Corp Operating Income (Loss) for the twelve months ending 30 Sep 2025 was $1.49B, a 16.7% increase year-over-year.
  • UNITED THERAPEUTICS Corp annual Operating Income (Loss) for 2024 was $1.38B, a 16.2% increase from 2023.
  • UNITED THERAPEUTICS Corp annual Operating Income (Loss) for 2023 was $1.18B, a 20.9% increase from 2022.
  • UNITED THERAPEUTICS Corp annual Operating Income (Loss) for 2022 was $980M, a 76.2% increase from 2021.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Change (%)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Change (%)

UNITED THERAPEUTICS Corp Quarterly Operating Income (Loss) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 $1.49B $389M +$45.4M +13.2% 01 Jul 2025 30 Sep 2025 10-Q 29 Oct 2025
Q2 2025 $1.45B $365M +$44.6M +13.9% 01 Apr 2025 30 Jun 2025 10-Q 30 Jul 2025
Q1 2025 $1.4B $383M +$26.5M +7.44% 01 Jan 2025 31 Mar 2025 10-Q 30 Apr 2025
Q4 2024 $1.38B $358M +$97.6M +37.5% 01 Oct 2024 31 Dec 2024 10-K 26 Feb 2025
Q3 2024 $1.28B $343M +$16.1M +4.92% 01 Jul 2024 30 Sep 2024 10-Q 29 Oct 2025
Q2 2024 $1.26B $320M +$6.5M +2.07% 01 Apr 2024 30 Jun 2024 10-Q 30 Jul 2025
Q1 2024 $1.26B $356M +$71.9M +25.3% 01 Jan 2024 31 Mar 2024 10-Q 30 Apr 2025
Q4 2023 $1.18B $260M +$84.5M +48.1% 01 Oct 2023 31 Dec 2023 10-K 26 Feb 2025
Q3 2023 $1.1B $327M +$12.7M +4.04% 01 Jul 2023 30 Sep 2023 10-Q 30 Oct 2024
Q2 2023 $1.09B $313M +$112M +55.3% 01 Apr 2023 30 Jun 2023 10-Q 31 Jul 2024
Q1 2023 $976M $284M -$3.6M -1.25% 01 Jan 2023 31 Mar 2023 10-Q 01 May 2024
Q4 2022 $980M $176M +$5.8M +3.42% 01 Oct 2022 31 Dec 2022 10-K 26 Feb 2025
Q3 2022 $974M $314M +$85.6M +37.4% 01 Jul 2022 30 Sep 2022 10-Q 01 Nov 2023
Q2 2022 $888M $202M -$20.4M -9.18% 01 Apr 2022 30 Jun 2022 10-Q 02 Aug 2023
Q1 2022 $909M $288M +$353M 01 Jan 2022 31 Mar 2022 10-Q 03 May 2023
Q4 2021 $556M $170M +$105M +160% 01 Oct 2021 31 Dec 2021 10-K 21 Feb 2024
Q3 2021 $451M $229M +$7.6M +3.44% 01 Jul 2021 30 Sep 2021 10-Q 02 Nov 2022
Q2 2021 $444M $222M +$81.7M +58.1% 01 Apr 2021 30 Jun 2021 10-Q 03 Aug 2022
Q1 2021 $362M -$64.8M -$232M -139% 01 Jan 2021 31 Mar 2021 10-Q 04 May 2022
Q4 2020 $594M $65.3M +$1.8M +2.84% 01 Oct 2020 31 Dec 2020 10-K 22 Feb 2023
Q3 2020 $592M $221M +$37.7M +20.6% 01 Jul 2020 30 Sep 2020 10-Q 03 Nov 2021
Q2 2020 $554M $141M -$80.9M -36.5% 01 Apr 2020 30 Jun 2020 10-Q 04 Aug 2021
Q1 2020 $635M $167M +$823M 01 Jan 2020 31 Mar 2020 10-Q 05 May 2021
Q4 2019 -$188M $63.5M -$68M -51.7% 01 Oct 2019 31 Dec 2019 10-K 24 Feb 2022
Q3 2019 -$120M $183M +$33.8M +22.6% 01 Jul 2019 30 Sep 2019 10-Q 28 Oct 2020
Q2 2019 -$153M $221M +$4M +1.84% 01 Apr 2019 30 Jun 2019 10-Q 29 Jul 2020
Q1 2019 -$157M -$656M -$963M -314% 01 Jan 2019 31 Mar 2019 10-Q 29 Apr 2020
Q4 2018 $805M $132M -$7.5M -5.4% 01 Oct 2018 31 Dec 2018 10-K 24 Feb 2021
Q3 2018 $813M $150M -$174M -53.8% 01 Jul 2018 30 Sep 2018 10-Q 30 Oct 2019
Q2 2018 $987M $217M +$129M +146% 01 Apr 2018 30 Jun 2018 10-Q 31 Jul 2019
Q1 2018 $858M $307M +$43.3M +16.4% 01 Jan 2018 31 Mar 2018 10-Q 01 May 2019
Q4 2017 $815M $139M -$35.2M -20.2% 01 Oct 2017 31 Dec 2017 10-K 26 Feb 2020
Q3 2017 $850M $324M +$85.2M +35.7% 01 Jul 2017 30 Sep 2017 10-Q 31 Oct 2018
Q2 2017 $765M $88.5M -$197M -69% 01 Apr 2017 30 Jun 2017 10-Q 01 Aug 2018
Q1 2017 $962M $264M -$100M -27.5% 01 Jan 2017 31 Mar 2017 10-Q 02 May 2018
Q4 2016 $1.06B $174M +$19.2M +12.4% 01 Oct 2016 31 Dec 2016 10-K 27 Feb 2019
Q3 2016 $1.04B $239M -$148M -38.3% 01 Jul 2016 30 Sep 2016 10-Q 25 Oct 2017
Q2 2016 $1.19B $285M +$113M +66% 01 Apr 2016 30 Jun 2016 10-Q 27 Jul 2017
Q1 2016 $1.08B $364M +$379M 01 Jan 2016 31 Mar 2016 10-Q 26 Apr 2017
Q4 2015 $699M $155M -$23.6M -13.2% 01 Oct 2015 31 Dec 2015 10-K 21 Feb 2018
Q3 2015 $723M $387M +$419M 01 Jul 2015 30 Sep 2015 10-Q 27 Oct 2016
Q2 2015 $303M $172M -$4.52M -2.56% 01 Apr 2015 30 Jun 2015 10-Q 28 Jul 2016
Q1 2015 $308M -$14.8M -$231M -107% 01 Jan 2015 31 Mar 2015 10-Q 28 Apr 2016
Q4 2014 $539M $179M +$207M 01 Oct 2014 31 Dec 2014 10-K 22 Feb 2017
Q3 2014 $332M -$32.2M -$137M -131% 01 Jul 2014 30 Sep 2014 10-Q 27 Oct 2015
Q2 2014 $469M $176M +$54M +44.2% 01 Apr 2014 30 Jun 2014 10-Q 28 Jul 2015
Q1 2014 $415M $216M +$122M +130% 01 Jan 2014 31 Mar 2014 10-Q 28 Apr 2015
Q4 2013 $292M -$28.5M -$157M -122% 01 Oct 2013 31 Dec 2013 10-K 25 Feb 2016
Q3 2013 $450M $105M +$23.9M +29.6% 01 Jul 2013 30 Sep 2013 10-Q 28 Oct 2014
Q2 2013 $426M $122M +$16.7M +15.8% 01 Apr 2013 30 Jun 2013 10-Q 29 Jul 2014
Q1 2013 $409M $94M -$12.7M -11.9% 01 Jan 2013 31 Mar 2013 10-Q 29 Apr 2014
Q4 2012 $422M $129M +$65.1M +102% 01 Oct 2012 31 Dec 2012 10-K 24 Feb 2015
Q3 2012 $357M $80.7M -$22.3M -21.6% 01 Jul 2012 30 Sep 2012 10-Q 29 Oct 2013
Q2 2012 $379M $106M -$8.91M -7.78% 01 Apr 2012 30 Jun 2012 10-Q 25 Jul 2013
Q1 2012 $388M $107M +$69.9M +190% 01 Jan 2012 31 Mar 2012 10-Q 25 Apr 2013
Q4 2011 $318M $63.5M +$48.2M +314% 01 Oct 2011 31 Dec 2011 10-K 25 Feb 2014
Q3 2011 $270M $103M +$40.5M +64.8% 01 Jul 2011 30 Sep 2011 10-Q 01 Nov 2012
Q2 2011 $229M $114M +$53.3M +87% 01 Apr 2011 30 Jun 2011 10-Q 26 Jul 2012
Q1 2011 $176M $36.8M +$4.56M +14.1% 01 Jan 2011 31 Mar 2011 10-Q 26 Apr 2012
Q4 2010 $171M $15.4M 01 Oct 2010 31 Dec 2010 10-K 26 Feb 2013
Q3 2010 $62.5M 01 Jul 2010 30 Sep 2010 10-Q 27 Oct 2011
Q2 2010 $61.2M 01 Apr 2010 30 Jun 2010 10-Q 28 Jul 2011
Q1 2010 $32.2M 01 Jan 2010 31 Mar 2010 10-Q 28 Apr 2011

UNITED THERAPEUTICS Corp Annual Operating Income (Loss) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $1.38B +$192M +16.2% 01 Jan 2024 31 Dec 2024 10-K 26 Feb 2025
2023 $1.18B +$205M +20.9% 01 Jan 2023 31 Dec 2023 10-K 26 Feb 2025
2022 $980M +$424M +76.2% 01 Jan 2022 31 Dec 2022 10-K 26 Feb 2025
2021 $556M -$37.7M -6.35% 01 Jan 2021 31 Dec 2021 10-K 21 Feb 2024
2020 $594M +$781M 01 Jan 2020 31 Dec 2020 10-K 22 Feb 2023
2019 -$188M -$993M -123% 01 Jan 2019 31 Dec 2019 10-K 24 Feb 2022
2018 $805M -$9.5M -1.17% 01 Jan 2018 31 Dec 2018 10-K 24 Feb 2021
2017 $815M -$247M -23.2% 01 Jan 2017 31 Dec 2017 10-K 26 Feb 2020
2016 $1.06B +$363M +51.9% 01 Jan 2016 31 Dec 2016 10-K 27 Feb 2019
2015 $699M +$160M +29.7% 01 Jan 2015 31 Dec 2015 10-K 21 Feb 2018
2014 $539M +$246M +84.2% 01 Jan 2014 31 Dec 2014 10-K 22 Feb 2017
2013 $292M -$129M -30.6% 01 Jan 2013 31 Dec 2013 10-K 25 Feb 2016
2012 $422M +$104M +32.7% 01 Jan 2012 31 Dec 2012 10-K 24 Feb 2015
2011 $318M +$146M +85.5% 01 Jan 2011 31 Dec 2011 10-K 25 Feb 2014
2010 $171M 01 Jan 2010 31 Dec 2010 10-K 26 Feb 2013
* An asterisk sign (*) next to the value indicates that the value is likely invalid.